Abstract

Background

Vitamin D3 is a secosteroid that exerts its effect by binding to its nuclear receptor called vitamin D receptor (VDR), inducing apoptosis and thereby inhibiting cell proliferation in cancer cells. The VDR receptor, located in the nucleus, is known to regulate the functions of over 200 genes. Various allelic forms of hVDR have been discovered that increase susceptibility to various cancers. The VDR-Cdx2 polymorphism, located in the promoter region of exon 1e in the VDR gene, influences the functional activity of the receptor, since the hVDR lacks consensus TATA and CAAT boxes. The current investigation examines the association between VDR-Cdx2 polymorphism and breast cancer in premenopausal females from Southern Pakistan.

Methods

We conducted a case control study on 264 subjects (103 cases and 161 controls) who were recruited from a tertiary hospital located in Karachi, Pakistan. Genomic DNA was extracted from peripheral blood using a commercial kit method, and the VDR-Cdx2 polymorphism was genotyped using tetraprimer amplification refractory mutation system polymerase chain reaction (T-ARMS-PCR) method. Pearson chi square test was used to assess the association between VDR-Cdx2 polymorphism and breast cancer while genotype distribution in controls was evaluated by Hardy-Weinberg equilibrium (HWE). Breast cancer risk was calculated using odds ratios and 95% confidence intervals.

Results

The genotype distribution in the control group was in HWE ($p > 0.05$) for the VDR-Cdx2 polymorphism. A non-significant association was observed between VDR cdx2 polymorphism and breast cancer, however the GG genotype was at risk ($OR = 1.832$, 95% CI = 0.695–4.828) of developing breast cancer.
Conclusion
The GG genotype of Cdx2-VDR gene polymorphism may increase the risk of developing breast cancer in young female patients in South Pakistan. Further investigations examining additional single nucleotide polymorphisms (SNPs) in VDR are required to assess their relationships with breast cancer.

Introduction
In Pakistan, breast carcinoma is the most frequently diagnosed cancer and leading malignant disease. It is a major cause of death in Asian countries, accounting for one in five female patient deaths [1]. It is difficult to determine the epidemiology of breast carcinoma in the Pakistani population because the country lacks a functional national cancer registry system. However, Karachi, Pakistan, has the highest registered cases of breast carcinoma (38%) in female patients [2]. Breast carcinoma is a multifactorial disease that is caused by various environmental [3] and genetic factors [4, 5]. There are numerous risk factors for breast cancer development, including excessive estrogen stimulus [6], elevated birth weight [7], overweight and obese [8], familial cancer history [9, 10] and gene mutations while mutation in BRCA 1 and BRCA 2 tumor suppressor genes are the most prevalent cause of breast cancer in Pakistani population [11–13]. However, limited data is available on tumor protein (TP53), phosphatase and tension homolog (PTEN), checkpoint kinase 2 (CHEK2), and estrogen Receptor 1 (ESR) mutations involvement in the development of breast cancer. Pathogenesis of breast cancer has not been well characterized [14, 15], but data have been published demonstrating the defensive role of 1,25 (OH)2 vitamin D3 in certain cancers [16–18].

Vitamin D3 has anti-cancer activity, and the deficiency may affect breast cancer vulnerability since vitamin D plays an important role in regulation of cell growth, cell proliferation, cell differentiation and cell death [19]. A previous study on Pakistani population has reported 95.6% of breast cancer patients along with 77% of healthy females as being vitamin D deficient [20] which is in contrary to the findings in developed countries.

Vitamin D is known to mediate its action in an intracrine or autocrine manner via binding to its receptor VDR [21, 22] which is expressed in most body tissues as well as on cancerous cells. The vitamin D receptor gene is a broadly studied candidate gene that resides in chromosome 12q region 14, consisting of a 5’ non translated promoter region and 5 exons. The DNA binding domains are encoded by exons 1A, 1B and 1C along with exons 2 and 3, whereas the ligand binding domains are encoded by exons 4 and 5 [23]. It has been previously demonstrated that VDR expression is reduced in cancer cells [24], which may be influenced by polymorphisms within the gene and increase breast cancer incidence [25]. Over 200 polymorphisms have been discovered in the VDR gene in different individuals, and Cdx2, Fok1, Apa1, Taq1 and Bsm1 are the most commonly studied polymorphisms. Several studies have been carried out to evaluate the relationship between VDR gene polymorphisms and breast cancer risk [26–29]. A meta-analysis on Caucasian women has demonstrated that VDR (Fok1, Bsm1, Apa1 and Taq1) polymorphisms may not be associated with increase breast cancer susceptibility [30] which is in contrary to the findings of Zhang and Song [31] in which a strong association between Fok1 VDR polymorphism and breast cancer has been reported. Others have also highlighted Fok1 SNP as the most notorious polymorphism of VDR gene influencing breast cancer susceptibility [25, 32, 33]. Among all VDR polymorphisms limited data is available on VDR-Cdx2 polymorphism and breast cancer susceptibility.
Cdx2 which is an intestine-specific transcription factor is known to regulate proliferation and differentiation of cells. Cdx2 is generally a protective polymorphism, particularly in osteoporosis [34, 35]. However, the published data examining the relationship between VDR Cdx2 variants and breast cancer susceptibility have been contradictory [25, 27, 36, 37].

The polymorphism of Cdx2 in VDR gene is located in the exon 1 promoter region of VDR gene and is a guanine/adenine (G/A) sequence variation [38]. The frequency of the A allele is 74% in Africans, 43% in Asians and 19% in Caucasians [39]. The A allele allows the Cdx2 transcription factor to bind more effectively, thereby increasing VDR transcriptional activity thus decreasing the breast cancer incidence [40], whereas the G allele has the opposite effect [34,36]. The CDx2 AG genotype has been reported to decrease breast cancer risk, whereas the AA genotype increases this risk [27]. Another study observed that the A allele may increase bone mineral density by increasing intestinal VDR expression, allowing for increased intestinal calcium absorption [34, 41]. Conversely, a study observed no correlation between the VDR Cdx2 polymorphism and breast cancer incidence [37].

Undeniably, adequate research has not been performed to determine the potential link between Cdx2 and breast cancer development in Pakistan. The linkage disequilibrium (LD) pattern between the Cdx2 and other VDR polymorphisms has not been studied with respect to breast cancer risk [37]. In conclusion, there are no data concerning the VDR Cdx2 polymorphism in the Pakistan population.

**Materials and Method**

**Ethics Statement**

The study was approved by the Board of Advanced Studies and Research (Approval#10(27) 28032012), University of Karachi and the Ethical Review Board of Departmental Research Committee (DRC), Department of Physiology, University of Karachi prior to its commencement. Written informed consent was obtained from all subjects prior to sample collection.

**Study population**

The present investigation is a retrospective, cohort case (n = 103) control (n = 161) study performed in pre-menopausal subjects with documented breast cancer diagnosis based on histopathology results. Subjects were recruited from September 2012 to July 2014 at a tertiary hospital located south of Karachi, while control subjects were healthy volunteer females selected randomly having no prior history of cancer. Inclusion criteria: Subjects between the ages of 18 and 45 years, parous, nulliparous and premenopausal, with or without a positive family history of breast cancer were included. All other subjects were excluded.

**DNA extraction**

Genomic DNA was extracted from peripheral blood using a commercial kit method (Gene JET Genomic DNA Purification Kit, Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania). Briefly, 200 μl whole blood, 400 μl R.B.C lysis solution and 20 μl proteinase K were mixed in a 1.5 ml eppendorf tube and incubated at 56°C for 10 min, followed by the addition of 500 μl 96% ethanol. Subsequently, whole lysate was pipetted into a DNA purification column and centrifuged at 13000 rpm for 1 min at 4°C. The column was washed with 500 μl of wash buffers I and II for 1 min each at 13000 rpm. Genomic DNA was eluted using 100 μl elution buffer and stored at -86°C for further investigation.
PCR analysis

The Cdx2 VDR gene polymorphism (rs 11568820) was genotyped using the polymerase chain reaction method as described earlier [42]. The G-Forward (5’-AGGATAGGAAAAATAATAGAAAACATT-3’) and Reverse (5’-AACCCATAATAAGGTTTTTAC-3’) primers, specifically amplify the G allele, with a product size of 110 bp. The A-Forward (5’-TCCTGAGTAAACTAGGTCACAA-3’) and Reverse (5’-ACGTTAAGTTCAGAAAGATTAC-3’) primer pairs specifically amplify the A allele, with a product size of 235 bp. A 297 bp internal control was amplified using the G-Forward and A-Reverse primers. The reaction was performed in a total volume of 50 μl using KapaTaq DNA polymerase master mix (KapaBiosystems, USA). Briefly, 25 μl of 2x master mix, 0.3 μl of each primer pair (25 pmol), 3 μl of genomic DNA and 20.2 μl of water were amplified in an automated thermal cycler (Veriti, Applied Biosystem, USA) under the following conditions: Initial denaturation at 95°C (5 min), 40 cycles of 95°C (30 sec), 56°C (45 sec), and 72°C (45 sec), followed by a final extension at 72°C for 5 min. The amplicons were electrophoresed with a 100 bp ladder (Fermentas, USA) on an 8% polyacrylamide gel at 30 mA for 1 hr, followed by staining with 0.5 μg/ml ethidium bromide. Gel images were obtained using the ChemiDoc-it2 (UVP, UK) Vision works LS software (version 7.1).

Statistical Analysis

Statistical analysis was performed using SPSS (version 17), with statistical significance set at p<0.05. Hardy-Weinberg equilibrium (HWE) was evaluated by Chi-square test in control. We used unconditional logistic regression to calculate the odds ratios with 95% confidence interval. Pearson chi-square ($\chi^2$) and odd ratios with 95% confidence intervals were calculated to assess the strength of association between VDR Cdx2 polymorphism and breast cancer risk. Odds ratios were also calculated for allele frequency comparison (G vs A), homozygote comparison (GG vs AA), dominant model (AA+GA vs GG), and recessive model (GG+GA vs AA).

Results and Discussion

Breast cancer prognosis in Pakistan remains uncertain because the country lacks a cancer registry system. This was a major impediment to the present study because reliable disease prevalence data could not be obtained. Breast cancer remains the most threatening and devastating cancer among women throughout the world, particularly in Pakistan. However, its pathogenesis, similar to other cancers, remains unclear. Several risk factors have been highlighted, including genetic predisposition [14, 15, 43]. Lifestyle remains a major contributor to breast cancer onset. Vitamin D, synthesized in the skin after sun exposure, and its metabolites (D3) have been reported to have an inverse relationship with breast cancer risk [44, 45]. However, vitamin D3 stimulates the transcription of multiple genes involved in cellular differentiation via its receptor, VDR, [44] located in the cell nucleus. VDR expression is influenced by single nucleotide polymorphisms (SNPs) [46, 47]. Over 200 SNPs have been identified in VDR; however, the polymorphisms most commonly associated with tumorigenesis are Fok 1 (ff) [48], Bsm 1 (bb) [49], Apa 1 (AA) [50], and Cdx2 (AA) [36], with Cdx2 being the least studied. To date, no data have been reported concerning the association between VDR polymorphisms and breast cancer in the Pakistani population. Therefore, we examined the risk and association between the VDR-Cdx2 polymorphism and breast cancer in Southern Pakistani females. It was previously identified that the structure of VDR gene is divided in three basic regions: 5’ untranslated (UTR) promoter region (Cdx2), coding regions (Fok 1, Bsm 1, Apa 1, Taq 1, Tru 91) and 3’ UTR regulatory region (poly A tail) because Cdx2 lie in 5’ UTR promoter region that’s why we considered only this SNP for evaluating the association with breast cancer risk.
This case control study consisted of 103 patients and 161 healthy controls with a mean age of 35±6 years. The breast cancer-related clinical characteristics of the study population are summarized in Table 1. The distribution of ER+/−, PR+/− and Her2neu+/− among patients was 1:0.23, 1:0.25 and 1:0.06, respectively. These factors have historically been employed to aid in the clinical management of breast cancer [51]. The majority of cases were invasive ductal carcinoma (91%) with disease stage grade II (56%) and III (33%), however a few cases of invasive papillary carcinoma (3%), ductal carcinoma in situ (DCIS, 2%) and others was also observed. Unfortunately, in Pakistani society, breast cancer cases are identified at later stages because of societal inhibitions, despite the disease being curable when identified at an early stage.

The breast cancer risk factors and anthropometric characteristics of patients and controls are depicted in Table 2. This study showed that the breast cancer risk significantly increases with increasing body weight (BMI > 25) and increasing waist to hip ratio (WHR > 0.85) whereas early menarche (< 12 yrs), lengthy menstrual phase, first birth at late ages (> 25 yrs), positive family history of breast cancer and all subjects who took oral contraceptives (OC) and receiving hormone replacement therapy (HRT) may also be at higher risk of breast cancer but these findings were not statistically significant. On contrary, other factors (nulliparity, no lactational history and positive family history of other cancers) were not associated with the breast cancer risk.

Other factors that modify the breast cancer such as grade, ER/PR status and Her2 neu status of breast cancer which were determined and difference were observed among cases. Low grade and ER+ve exhibited slightly higher risk of carrying GG genotype but these findings were not significant statistically (Table 3).

The genotype distribution of GG (53), GA (37), and AA (7) among breast cancer patients was obtained in 97 samples out of 103; however, in controls, it was 62, 84 and 15 respectively. The genotype distribution of control was in Hardy-Weinberg equilibrium with p-value 0.07 (Table 4). Our results also demonstrated no-association (Pearson’s $\chi^2 = 0.032$, p-value = 0.984) between the Cdx2 polymorphism and breast cancer, while an odds ratio via binary logistic

| Table 1. Breast cancer clinical characteristics. |
|-----------------------------------------------|
| Clinical Characteristics | Cases (n = 97) |
|--------------------------|---------------|
| **Type of Breast cancer** |               |
| Invasive ductal carcinoma | 88            |
| Invasive Papillary Carcinoma | 3           |
| Invasive ductal carcinoma in situ (DCIS) | 2               |
| Others                    | 4             |
| **Grades of cancer**     |               |
| GI                        | 6             |
| GII                       | 54            |
| GIII                      | 32            |
| GIV                       | 5             |
| **Estrogen receptor status** |           |
| ER+ve (0 to +9)            | 34            |
| ER-ve (-1 to-2)            | 8             |
| **Progesterone receptor status** |         |
| PR+ve (+0 to +8)           | 31            |
| PR-ve (-1 to-2)            | 8             |
| **Her 2 neu (erb 2 oncprotein)** |     |
| +ve (0 to +3)              | 31            |
| -ve (-1 to-2)              | 2             |

doi:10.1371/journal.pone.0122657.t001
regression analysis of 1.832 (95%CI = 0.695–4.828) was observed for the GG genotype (Table 5). The observed allele frequency difference was non-significant (G vs A allele, P = 0.109; OR = 1.578; 95%CI = 0.903–2.758). An odds ratio for GG vs AA model is 1.832 (95%CI = 0.695–4.828), recessive model (GG+GA vs AA) OR = 1.321 (95%CI = 0.519–3.364) and dominant model (AA+GA vs GG) OR = 0.754 (95%CI = 0.453–1.257) were non-significant.

Table 2. Risk factors associated with the Breast cancer.

| Factors                        | Cases n | Controls n | χ2    | P-value | OR (95%CI)* | P-value |
|-------------------------------|---------|------------|-------|---------|-------------|---------|
| Menarcheal age                |         |            |       |         |             |         |
| >14                           | 9       | 11         |       |         | 1           |         |
| 12–14                         | 88      | 146        | 2.347 | 0.039   | 0.737 (0.294–1.848) | 0.515   |
| <12                           | 6       | 4          |       |         | 1.833 (0.392–8.566) | 0.441   |
| Cycle length                  |         |            |       |         |             |         |
| Normal (3–7)                  | 95      | 141        |       | 1       |             |         |
| Short (1–2)                   | 3       | 14         | 3.606 | 0.0165  | 0.318 (0.089–1.137) | 0.078   |
| Long (> 7)                    | 5       | 6          |       |         | 1.273 (0.3674–4.169) | 0.732   |
| Parity                        |         |            |       |         |             |         |
| Parous                        | 85      | 25         | 122.262 | 0.001  | 1           |         |
| Nulliparous                   | 18      | 136        |       |         | 0.034 (0.017–0.067) | 0.000   |
| Age at first birth            |         |            |       |         |             |         |
| <20                           | 22      | 3          | 1.118 | 0.373   | 0.711 (0.114–4.442) | 0.715   |
| 20–24                         | 34      | 7          |       |         | 1.079 (0.19–6.117) | 0.931   |
| 25–29                         | 16      | 5          |       |         | 1.63 (0.232–11.455) | 0.624   |
| >29                           | 9       | 2          |       |         |             |         |
| Lactational history           |         |            |       |         |             |         |
| Yes                           | 83      | 23         | 112.407 | 0.001  | 1           |         |
| No                            | 20      | 138        |       |         | 0.042 (0.022–0.081) | 0.000   |
| BMI                           |         |            |       |         |             |         |
| Normal (18–25)                | 42      | 82         |       |         |             |         |
| Underweight (<18)             | 7       | 52         | 45.717 | 0.001  | 0.263 (0.110–0.629) | 0.003   |
| Overweight (25–30)            | 39      | 20         |       |         | 3.807 (1.978–7.328) | 0.000   |
| Obesity (>30)                 | 15      | 7          |       |         | 4.184 (1.584–11.04) | 0.004   |
| W/H ratio                     |         |            |       |         |             |         |
| Acceptable (<0.85)            | 11      | 85         | 45.789 | 0.001  | 1           |         |
| Uacceptable (>0.85)           | 92      | 76         |       |         | 8.139 (4.211–15.732) | 0.000   |
| Family history                |         |            |       |         |             |         |
| No                            | 81      | 131        |       |         |             |         |
| Yes                           | 22      | 30         | 0.295 | 0.587   | 1.186 (1.384–5.876) | 0.587   |
| F.H of other cancer           |         |            |       |         |             |         |
| No                            | 88      | 131        |       |         |             |         |
| Yes                           | 15      | 30         | 0.273 | 0.601   | 1.083 (0.429–1.632) | 0.602   |
| O.C                           |         |            |       |         |             |         |
| No                            | 93      | 148        |       |         |             |         |
| Yes                           | 10      | 13         | 0.211 | 0.646   | 1.224 (0.516–2.905) | 0.646   |
| H.R.T                         |         |            |       |         |             |         |
| No                            | 98      | 158        |       |         |             |         |
| Yes                           | 5       | 3          | 1.912 | 0.167   | 2.687 (0.628–11.494) | 0.183   |

*Odds ratios and 95% CI was calculated by logistic regression analysis

doi:10.1371/journal.pone.0122657.t002
The results from our study revealed a non-significant association between VDR-Cdx2 gene polymorphism and breast cancer among premenopausal Pakistani females, while the published findings on the relationship between VDR Cdx2 polymorphisms and breast cancer incidence are conflicting [27, 36, 38] since a significant association has been documented in an African population [27] only. However a study on colorectal cancer risk [52] and prostate cancer

Table 3. Association of AA and GG genotype in relation to its covariates.

| Variables                 | n  | GG+GA | AA   | *OR (95%CI) | P-Value | AA+GA | GG    | *OR (95%CI) | P-Value |
|---------------------------|----|-------|------|-------------|---------|-------|-------|-------------|---------|
| Grades of cancer          |    |       |      |             |         |       |       |             |         |
| GI                        | 6  | 5     | 1    | 1.00 (0.294–3.83) | 0.326   | 3     | 3     | 1.00 (0.268–7.153) | 0.697   |
| GII                       | 54 | 51    | 3    | 0.571 (0.044–6.019) | 0.598   | 13    | 19    | 0.45 (0.09–2.244) | 0.33    |
| GIII                      | 32 | 29    | 3    | 2.00 (0.999–5.154)  | 0.56    | 3     | 2     | 0.5 (0.048–5.154)  | 0.56    |
| Estrogen receptor status   |    |       |      |             |         |       |       |             |         |
| ER-ve (-1 to-2)           | 8  | 8     | 0    | 0.294 (0.025–3.383) | 0.326   | 4     | 4     | 1.00 (0.268–7.153) | 0.697   |
| ER+ve (0 to +9)           | 34 | 34    | 0    | NC**        |         | 16    | 18    | 1.125 (0.241–5.252) | 0.881   |
| Progesterone receptor status |   |       |      |             |         |       |       |             |         |
| PR-ve (-1 to-2)           | 8  | 8     | 0    | 0.294 (0.025–3.383) | 0.326   | 4     | 4     | 1.00 (0.268–7.153) | 0.697   |
| PR+ve (+0 to +8)          | 31 | 31    | 0    | NC**        |         | 14    | 17    | 0.729 (0.148–3.596) | 0.697   |
| Her 2 neu                 |    |       |      |             |         |       |       |             |         |
| -ve (-1 to-2)             | 2  | 2     | 0    | 0.294 (0.025–3.383) | 0.326   | 4     | 4     | 1.00 (0.268–7.153) | 0.697   |
| +ve (0 to +3)             | 31 | 31    | 0    | NC**        |         | 14    | 17    | 0.729 (0.148–3.596) | 0.697   |

*Unconditional logistic regression analysis
**Not calculated

doi:10.1371/journal.pone.0122657.t003

Table 4. Genotype distribution in the Hardy-Weinberg equilibrium.

| Genotype | Observed value (n) | Predictive value (n) | \(\chi^2\) | p-value |
|----------|--------------------|----------------------|-----------|---------|
| GG       | 62                 | 67.2                 |           |         |
| GA       | 84                 | 73.6                 | 3.18      | 0.07    |
| AA       | 15                 | 20.2                 |           |         |

doi:10.1371/journal.pone.0122657.t004

Table 5. Association between VDR Cdx2 polymorphism and BC risk.

| Genotype | Cases (n) | Controls (n) | \(\chi^2\) | p-value | *OR (95% CI) | p-value |
|----------|-----------|--------------|-----------|---------|-------------|---------|
| AA       | 7         | 15           | 0.032     | 0.984   | 1           |         |
| GA       | 37        | 84           |           |         | 0.944 (0.355–2.507) | 0.908   |
| GG       | 53        | 62           |           |         | 1.832 (0.695–4.828) | 0.221   |
| Total    | 97        | 161          |           |         | 1.578 (0.903–2.758) | 0.109   |
| A        | 25.5      | 57           |           |         | 1           |         |
| G        | 71.5      | 104          |           |         | 1.578 (0.903–2.758) | 0.109   |
| GG vs AA | 53/7      | 62/15        |           |         | 1.832 (0.695–4.828) | 0.221   |
| GG+GA vs AA | 90/7    | 146/15       |           |         | 1.321 (0.519–3.364) | 0.559   |
| AA+GA vs GG | 44/53   | 99/62        |           |         | 0.754 (0.453–1.257) | 0.279   |

*Unconditional logistic regression analysis

doi:10.1371/journal.pone.0122657.t005

The results from our study revealed a non-significant association between VDR-Cdx2 gene polymorphism and breast cancer among premenopausal Pakistani females, while the published findings on the relationship between VDR Cdx2 polymorphisms and breast cancer incidence are conflicting [27, 36, 38] since a significant association has been documented in an African population [27] only. However a study on colorectal cancer risk [52] and prostate cancer
with VDR Cdx2 has reported a significant and non-significant association respectively. Our results showed an odds ratio (OR) for VDR-Cdx2 G allele as 1.578 (95%CI = 0.903–2.758, \( p = 0.109 \)), which is in agreement with previous study [34] who had identified that Cdx2-G allele is responsible to lower the transcriptional activity of VDR gene. The decrease in transcriptional activity of VDR alters the various protective mechanism regulated by vitamin D3 (Fig. 1). Studies have documented that Cdx2 may promote tumor development [55, 56, 57].

![Signaling pathway indicating the relationship between Cdx2 VDR and breast cancer.](https://example.com/signaling-pathway.png)

Fig 1. Signaling pathway indicating the relationship between Cdx2 VDR and breast cancer. See text for further details. CaR = Calcium receptors, PI-PLC = Phosphotidyl inositol—phospholipase C, ERK ½ = Extracellular signal regulated kinases 1 and 2, MAPK = Mitogen activated protein kinases, RXR A and B = Retinoid X receptor A and B, VDRE = vitamin D receptor response element.

doi:10.1371/journal.pone.0122657.g001
while other studies have identified it as a tumor suppressor [58, 59, 60]. Since VDR-Cdx2 domain regulates the expression of VDR gene in mammary tissue as the human VDR promoter domain lacks consensus TATA and CAAT boxes [61]. Therefore the homeo domain may play a vital role in regulating tumor suppressor gene (BRCA1 gene) [62] and prevents estrogen induced ductal proliferation and differentiation [63, 64] leading to prevention in breast cancer development. Additionally vitamin D through VDR induces apoptosis in breast tissue via down regulation of the anti-apoptotic protein (Bcl-2) [18] and inhibition of angiogenesis in mammary tissues [65, 66].

Strengths and Limitations
The study has the strength that it attempts to answer the probable contribution of vitamin D receptor genes in breast cancer among premenopausal Pakistani females. Since a significant haplotype differences between cases and controls may play a role in influencing vitamin D supplementation to improve health status of breast cancer subjects.

Present investigation has the limitation of relatively small sample size along with the single SNP of VDR gene. These limitations could be improved by enrolling a greater number of individuals, studying additional VDR-SNPs, evaluating serum vitamin D3 levels, and assessing various clinicopathological parameters and other risk factors. However, this study is the first performed in pre-menopausal breast cancer cases in South Asia, specifically in Pakistan.

Conclusions
The GG genotype of VDR-Cdx2 polymorphism may increase the risk of breast cancer in females from Karachi, Pakistan. The present study should prompt further large-scale studies of premenopausal breast cancer predisposition genes in larger sample sizes and the collection of additional demographic data related to ethnicity, diet, lifestyle, reproductive hormone levels, oral contraceptive usage and other environmental factors.

Author Contributions
Conceived and designed the experiments: MI TA. Performed the experiments: MI TA. Analyzed the data: MI TA. Contributed reagents/materials/analysis tools: MI TA. Wrote the paper: MI TA SAM. Assisted in sampling: SAM.

References
1. Pakistan Medical Research Council (1977) Collection of data of various types of tumors in Pakistan. (PMRC Monograph No. 1). Karachi: PMRC.
2. Hanif M, Zaidi P, Kamal S, Hameed A (2009) Institution-based Cancer Incidence in a Local Population in Pakistan: Nine Year Data Analysis. Asian Pacific J. Cancer Prev. 10, 227–230. PMID: 19537889
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343(2):78–85. doi:10.1056/NEJM200007133430201 PMID: 10891514
4. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al (2010) Performance of common genetic variants in breast cancer risk models. N Engl J Med, 362(11):986–993. doi:10.1056/NEJMoa0907727 PMID: 20237344
5. Harris TJ, McCormick F (2010) The molecular pathology of cancer. Nat Rev Clin Oncol, 7:251–265. doi: 10.1038/nrclonc.2010.41 PMID: 20351699
6. Cheung KL (2007) Endocrine therapy for breast cancer: an overview. Breast, 16 (4):327–343. doi: 10.1016/j.breast.2007.03.004 PMID: 17499991
7. Silva IS, De-Stavola B, McCormack V (2008) Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. PLoS Med. doi: 10.1371/journal.pmed.0050193.
8. Zaman K, Bodmer A, Pralong F, Castiglione-Gertsch M (2012) Breast cancer and obesity, a dangerous relation. Rev Med Suisse, 8(342):1101–1104. PMID: 22734178
9. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol, 15(6):875–884. PMID: 15151943
10. Hankinson SE (2008) Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer. Adv Exp Med Biol, 617:161–169. doi: 10.1007/978-0-387-69080-3_15 PMID: 18497040
11. Malik FA, Ashraf S, Kayani A, Jiang WG, Mir A, Ansar M, et al., (2008) Contribution of BRCA1 germline mutation in patients with sporadic breast cancer. International Seminars in Surgical Oncology, vol. 5, published online. doi: 10.1186/1477-7800-5-21
12. Rashid MU1, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, et al., (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. International Journal of Cancer, vol. 119(12): 2832–2839. PMID: 16998791
13. Liede A, Malik IA, Aziz Z, De los Rios P, Kwan E, Narod SA (2008) Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. American Journal of Human Genetics, vol. 71(3): 595–606. PMID: 12181777
14. Amir E, Freedman OC, Seruga B, Evans DG (2010) Assessing women at high risk of breast cancer: a review of risk assessment models. JNatl Cancer Inst. 102:680–691. doi:10.1093/jnci/djq088 PMID: 20427433
15. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S (2010) Breast tissue composition and susceptibility to breast cancer. Adv Exp Med Biol, 617:161–169. doi:10.1007/978-0-387-69080-3_15 PMID: 18497040
16. Zmuda JM, Cauley JA, Ferrell RE (2009) Vitamin D receptor gene variants. Epidemiologic Reviews, 22 (2): 203–217. PMID: 11218372
17. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, et al. (2010) Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer, 10:483. doi:10.1186/1471-2407-10-483 PMID: 20831823
18. Tang C, Chen N, Wu M, Yuan H, Du Y (2009) Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat, 117:391–399. doi: 10.1007/s10549-008-0262-4 PMID: 19145484
19. Engel LS, Orlow I, Sima CS, Satagopan J, Mujumdar U, Roy P, et al. (2012) Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case–control study. Cancer Epidemiol. Biomarkers Prev. 21 (10): 1856–1867. doi:10.1158/1055-9965.EPI-12-0551 PMID: 22892281
20. Anderson LN, Cotterchio M, Cole DE, Knight JA (2011) Vitamin D related genetic variants, interactions with vitamin D exposure, and breast cancer risk among caucasian women in ontario. Cancer Epidemiol Biomarkers Prev., 20:1708–1717. doi:10.1158/1055-9965.EPI-11-0300 PMID: 21693626
21. Dalessandri KM, Mike R, Wiencke JK, Farrer G, Pugh TW, Manjeshwar S, et al. (2011) Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study. J. Am. Coll. Surg. 215 (5): 652–657. doi: 10.1016/j.jamcollsurg.2012.06.413 PMID: 22867716
29. Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, et al. (2011) Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U. S. Breast Cancer Res. Treat. 132 (2): 683–691. doi: 10.1007/s10549-011-1885-4 PMID: 22130867

30. Yang B, Liu S, Yang X, Wangc Y, Zhao X, Zheng D, et al. (2014) Current evidence on the four polymorphisms of VDR and breast cancer risk in Caucasian women. Meta Gene 2: 41–49. doi: 10.1016/j.
mgene.2013.09.008 PMID: 25606388

31. Zhang K, Song L (2014) Association between Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk: A Meta-Analysis of 39 Studies. PLoS ONE 9(4): e96125. doi: 10.1371/journal.pone.0096125 PMID: 24769568

32. Shahbazi S, Alavi S, Majidzadeh-A K, Ghaffarpour M, Soleimani A, Mahdian R (2013) BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med. Oncol. 30,393. doi: 10.1007/
s12032-012-0393-7 PMID: 23277283

33. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. (2004) Vitamin D receptor gene polymorphisms and breast cancer risk. Clin. Cancer Res. 10, 5472–5481. PMID: 15328186

34. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, et al. (2001) The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res, 16:1256–1264 PMID: 11450701

35. Brown MA, Haughton MA, Grant SF, Gunnell AS, Henderson NK, Eisman JA (2001) Genetic control of bone density and turnover: role of the collagen 1alpha1, estrogen receptor, and vitamin D receptor genes. J Bone Miner Res, 14: 758–764.

36. Yao S, Zipori G, Boivbqfjng DH, Jandorf L, Hong CC, Zhao H, et al. (2012) Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African–American women: a case–control study. Breast Cancer Res, 14:R58. doi: 10.1186/bcr3162 PMID: 22480149

37. Abbas S, Nieters A, Linseisen J, Slaenger T, Kropp S, Mutschelknauss EJ, et al. (2008) Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res, 10 (2): R31. doi: 10.1186/bcr1994 PMID: 18419802

38. Yamamoto H, Miyamoto K, Li B, Taketani Y, Kitano M, Inoue Y, et al. (1999) The caudal-related homeodomain Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J Bone Miner Res, 14: 240–247.

39. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA and VanLeeuwen JP (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene, 338: 143–156. PMID: 15315818

40. Zhou ZC, Wang J, Cai ZH, Zhang QH, Cai ZX, Wu JH et al. (2013) Association between vitamin D receptor gene Cdx2 polymorphism and breast cancer susceptibility. TumourBiol, 34(6):3437–41. doi: 10. 1007/s13277-013-0919-4 PMID: 23821301

41. Fang Y, van Meurs JB, Bergink AP, Hofman A, van Duijn CM, van Leeuwen JP, et al. (2003) Cdx-2 polymorphism in the promoter region of the human vitamin D receptor gene determines susceptibility to fracture in the elderly. J Bone Miner Res, 18: 1632–1641. PMID: 12966672

42. Marozik P, Mosse H, Aleva V, Rudenko E, Tamulinienė M, Ramanau H, et al. (2013) Association between Polymorphisms of VDR, COL1A1, and LCT Genes and Bone Mineral Density in Belarussian Women with Severe Postmenopausal Osteoporosis. Medicina (Kaunas), 49(4):20–26.

43. Jiao Z, Li D (2013) Lack of association between MHTFR Glu429Ala polymorphism and breast cancer susceptibility: a systematic review and meta-analysis of 29 research studies. Tumour Biol, 34:1225– 1233. doi: 10.1007/s13277-013-0665-7 PMID: 23393023

44. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA (2011) Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med, 155:827–838. doi: 10.7326/0003-4819-155-12-201112200-00005 PMID: 22184690

45. Mondul AM, Weinstein SJ, Horst RL, Purdue M, Albanes D (2012) Serum vitamin D and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial. Cancer Epidemiol Biomarkers Prev, 21:1222–1225. doi: 10.1158/1055-9965.EPI-12-0439 PMID: 22623707

46. Chen L, Davey SG, Evans DM, Cox A, Lawlor DA, Donovan J, et al. (2009) Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev, 18:2874–2881. doi: 10.1158/1055-9965.EPI-09-0544 PMID: 19861519

47. Touvier M, Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, et al. (2011) Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev, 20:1003–1016. doi: 10.1158/1055-9965.EPI-10-1141 PMID: 21378269
48. Chen W Y, Bertone-Johnson E R, Hunter D J, Willett W C, Hankinson S E (2005) Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14: 2335–2339. PMID: 16214913
49. Trabert B, Malone K E, Daling J R, Doody DR, Bernstein L, Ursin G, et al (2007) Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women. Breast Cancer Res 9: R84. PMID: 18067661
50. Sillanpää P, Hirvenoja A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, et al (2004) Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk. Pharmacogenetics. 14: 239–245. PMID: 15083068
51. Horwitz KB, McGuire WL (1975) Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science, 189:726–727. PMID: 168640
52. Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen B, et al (2012) Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol 18: 1672–1679. doi: 10.3748/wjg.v18.i14.1672 PMID: 22529698
53. Yin M, Wei S, Wei Q (2009) Vitamin D Receptor Genetic Polymorphisms and Prostate Cancer Risk: A Meta-analysis of 36 Published Studies. Int J Clin Exp Med. 2: 159–175. PMID: 19684888
54. John E M, Schwartz GG, Koo J, Van Den Berg D, Ingles SA (2005) Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 65: 5470–5479. doi: 10.1158/0008-5472.can-04-3134 PMID: 15958597
55. Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolós C, David L, et al (2003) Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol, 199:36–40. PMID: 12474224
56. Mutoh H, Sakurai S, Satoh K, et al (2004) Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res, 64:7740–7747. PMID: 15520178
57. Kang JM, Lee BH, Kim N, Lee HS, Lee HE, Park JH, et al (2011) CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. J Korean Med Sci, 26: 647–653. doi: 10.3346/jkms.2011.26.5.647 PMID: 21532856
58. Bai YQ, Yamamoto H, Akiyama Y, Swain GP, Moffett J, Sund NJ, Set al (2002) Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett, 8: 47–55.
59. Bonhomme C, Duluc I, Martin E, Chawengsaksophak K, Chenard MP, Kedinger M, et al (2003) The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development. Gut, 52: 1465–1471. PMID: 12970140
60. Qin R, Wang NN, Chu J, Wang X (2012) Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions. World J Gastroenterol, 18: 3296–3302. doi: 10.3748/wjg.v18.i25.3296 PMID: 22783055
61. Miyamoto K, Kesterson R A, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. (1997) Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol. 11:1165–1179.
62. Campbell M J, Gombart A F, Kwok S H, Park S, Koeffler H P (2000) The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 19:5091–5097. PMID: 11042697
63. Zinser G M, Welsh J (2004) Vitamin D receptor status alters mammmary gland morphology and tumorigenesis in MMTV-neu-mice. Carcinogenesis. 25: 2361–2372. PMID: 15333467
64. Zinser G M, Sundberg J P, Welsh J (2002) Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis. 23: 2103–2109. PMID: 12507934
65. Matsumoto H, Iino Y, Koibuchi Y, Andoh T, Horii Y, Takei H, et al. (1999) Antitumor effect of 22-oxacalciotriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep. 6:349–352. PMID: 10023003
66. Gonzalez-Sancho J M, Alvarez-Dolado M, Munoz A (1998) 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 426:225–228. PMID: 9599013